|4Feb 2, 4:05 PM ET

Ciaramella Giuseppe 4

4 · Beam Therapeutics Inc. · Filed Feb 2, 2026

Research Summary

AI-generated summary of this filing

Updated

Beam Therapeutics President Giuseppe Ciaramella Receives Award

What Happened
Giuseppe Ciaramella, President of Beam Therapeutics (BEAM), was granted 80,000 shares as a derivative award on January 31, 2026. The Form 4 records the transaction as an award/grant (code A) at $0.00 per share, indicating a compensation grant rather than a cash purchase or sale.

Key Details

  • Transaction date: 2026-01-31; Form 4 filed: 2026-02-02 (appears timely).
  • Amount granted: 80,000 (derivative award recorded at $0.00).
  • Vesting: Vests in equal monthly installments over the following 48 months, subject to continued service (footnote).
  • Shares owned after transaction: not specified in the provided filing excerpt.
  • Transaction type: Award/grant of stock option (not a market purchase or sale).

Context
This filing documents a compensation-related stock option grant that vests over four years. Such grants are common for executives and are part of pay/retention programs; they do not represent an immediate market purchase or sale of shares and therefore are not a direct signal of buying or selling intent.

Insider Transaction Report

Form 4
Period: 2026-01-31
Transactions
  • Award

    Stock Option (Right to Buy)

    [F1]
    2026-01-31+80,00080,000 total
    Exercise: $27.62Exp: 2036-01-31Common Stock (80,000 underlying)
Footnotes (1)
  • [F1]This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date.
Signature
By: /s/ Christine Bellon, Attorney-in-fact|2026-02-02

Documents

1 file
  • 4
    ownership.xmlPrimary

    4